161 related articles for article (PubMed ID: 34206229)
1. Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia.
Parigger T; Gassner FJ; Scherhäufl C; Bakar AA; Höpner JP; Hödlmoser A; Steiner M; Catakovic K; Geisberger R; Greil R; Zaborsky N
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206229
[TBL] [Abstract][Full Text] [Related]
2. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
3. Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
Gassner FJ; Zaborsky N; Catakovic K; Rebhandl S; Huemer M; Egle A; Hartmann TN; Greil R; Geisberger R
Br J Haematol; 2015 Aug; 170(4):515-22. PubMed ID: 25940792
[TBL] [Abstract][Full Text] [Related]
4. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
Gorgun G; Ramsay AG; Holderried TA; Zahrieh D; Le Dieu R; Liu F; Quackenbush J; Croce CM; Gribben JG
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6250-5. PubMed ID: 19332800
[TBL] [Abstract][Full Text] [Related]
5. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
6. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
[TBL] [Abstract][Full Text] [Related]
7. Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
Rovida A; Maccalli C; Scarfò L; Dellabona P; Stamatopoulos K; Ghia P
Clin Cancer Res; 2021 Feb; 27(3):729-739. PubMed ID: 33051305
[TBL] [Abstract][Full Text] [Related]
8. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
Hofbauer JP; Heyder C; Denk U; Kocher T; Holler C; Trapin D; Asslaber D; Tinhofer I; Greil R; Egle A
Leukemia; 2011 Sep; 25(9):1452-8. PubMed ID: 21606964
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
10. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
11. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
[TBL] [Abstract][Full Text] [Related]
12. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
Alhakeem SS; McKenna MK; Oben KZ; Noothi SK; Rivas JR; Hildebrandt GC; Fleischman RA; Rangnekar VM; Muthusamy N; Bondada S
J Immunol; 2018 Jun; 200(12):4180-4189. PubMed ID: 29712773
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
14. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
[TBL] [Abstract][Full Text] [Related]
15. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
[TBL] [Abstract][Full Text] [Related]
16. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
[TBL] [Abstract][Full Text] [Related]
17. CD74 is dispensable for development of chronic lymphocytic leukemia in
Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
[TBL] [Abstract][Full Text] [Related]
18. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
[TBL] [Abstract][Full Text] [Related]
20. A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia.
Goral A; Firczuk M; Fidyt K; Sledz M; Simoncello F; Siudakowska K; Pagano G; Moussay E; Paggetti J; Nowakowska P; Gobessi S; Barankiewicz J; Salomon-Perzynski A; Benvenuti F; Efremov DG; Juszczynski P; Lech-Maranda E; Muchowicz A
Front Immunol; 2022; 13():781364. PubMed ID: 35296093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
